ROCHESTER, N.Y., Aug. 29, 2013 /PRNewswire/ -- Bio-Optronics, the developer of Clinical Conductor Site CTMS, is thrilled to announce the successful CTMS implementation at over 1,600 clinical research sites around the world, making it the most widely used clinical trial management system. Designed specifically for research sites, Clinical Conductor Site CTMS is the premier tool for clinical research sites.
Sites that have adopted the Clinical Conductor Site CTMS platform have seen dramatic improvements in their overall operational effectiveness; many sites have reported up to a 20% increase in overall efficiency, while showing a 30% increase in profitability while using the software.
Company Vice President and COO Maria Durkin states, "Clinical Conductor Site CTMS has revolutionized the way sites conduct trials. Our customers are meeting recruitment targets more quickly, improving financial performance and managing trial documentation efficiently. Sites using Clinical Conductor are also differentiating themselves as successful research organizations that consistently meet deliverables and achieve results. We've seen our customers achieve significant growth in trials. We are proud to be working with them and appreciate the ongoing feedback that enables Clinical Conductor Site CTMS to continue to adapt and grow with the market's needs."
Clinical Conductor Site CTMS has helped research sites worldwide make a profound impact on the healthcare industry. Since its debut, Clinical Conductor Site CTMS has been used in nearly 40,000 trials and has tracked over 2 million trial patients, spanning single sites, multi-location sites, site networks and hospital departments. As Clinical Conductor Site CTMS continues to grow, we foresee additional ways in which researchers will be able to expand and optimize their businesses, while expediting delivery of critical new enhancements in medicine, throug
|SOURCE Bio-Optronics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved